← All themes Genomics & Gene Editing

Gene Therapy

Gene therapy delivers a working copy of a gene, or a correction to a faulty one, usually once and for life. Manufacturing the delivery vector is often harder than designing the therapy.

131 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Novartis NVS $287B	910	+5	+0.6%	$19.9B
2	2 Charles River Laboratories CRL $14.7B	300	+3	+1%	$4.2B
3	3 DELISTED bluebird bio BLUE	210	+11	+6%	$4.24B
4	4 DELISTED CATALENT, INC. CTLT	209	+3	+1%	$3.64B
5	5 Sarepta Therapeutics SRPT $1.87B	180	+2	+1%	$1.21B
6	6 Ultragenyx Pharmaceutical RARE $1.49B	165	-10	-6%	$2.76B
7	7 Precigen PGEN $2.64B	154	-17	-10%	$1.99B
8	8 DELISTED SANGAMO THERAPEUTICS INC SGMO	118	-8	-6%	$241M
9	9 PTC Therapeutics PTCT $5.11B	115	-8	-7%	$310M
10	ISEE 10 DELISTED IVERIC bio, Inc. Common Stock ISEE	100	-37	-27%	$97.4M
11	SIOX 11 DELISTED Sio Gene Therapies Inc. Common Stock SIOX	97	-4	-4%	$1.63B
12	BLCM 12 DELISTED Bellicum Pharmaceuticals, Inc. BLCM	96	+16	+20%	$263M
13	13 Lineage Cell Therapeutics LCTX $244M	96	+4	+4%	$161M
14	AGTC 14 DELISTED Applied Genetic Technologies Corporation AGTC	89	-1	-1%	$75.8M
15	15 Atara Biotherapeutics ATRA $95.2M	85	-1	-1%	$493M
16	16 Regenxbio RGNX $465M	85	+7	+9%	$401M
17	ATHX 17 DELISTED Athersys, Inc. Common Stock ATHX	76	-3	-4%	$33.7M
18	18 Intellia Therapeutics NTLA $1.64B	76	+6	+9%	$236M
19	19 DELISTED Adverum Biotechnologies ADVM	75	-8	-10%	$36.5M
20	20 Rocket Pharmaceuticals RCKT $259M	67	-15	-18%	$20.7M
21	21 Lakefront Biotherapeutics American Depositary Shares LKFT $1.97B	64	+12	+23%	$868M
22	22 Abeona Therapeutics ABEO $269M	58	+4	+7%	$71.6M
23	23 Fate Therapeutics FATE $232M	53	+16	+43%	$114M
24	ADAP 24 DELISTED Adaptimmune Therapeutics ADAP	49	+9	+23%	$219M
25	25 Fortress Biotech FBIO $64.7M	48	-3	-6%	$24M